Novartis aims to nearly triple biosimilar drugs on market by 2020

KUFSTEIN, Austria, June 20 (Reuters) - Switzerland's

Novartis pledged to nearly triple its number of

biosimilar drugs on the market by 2020, raising its bet that

cheaper versions of blockbuster...

Read more